Bayer has officially begun a Phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor designed to...
Read MoreEverest Medicines has announced groundbreaking results from its Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine kinase...
Read MoreTeva Pharmaceutical Industries has unveiled encouraging results from its Phase 3 SPACE study, highlighting the efficacy and safety of...
Read MoreIn a significant milestone for autoimmune disease research, argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative...
Read MoreEdinburgh-based biotech company Cytomos has announced a significant milestone, raising $5m (approximately £3.98m) in an oversubscribed funding round to...
Read MoreTeva Pharmaceuticals and Immunai, a leader in artificial intelligence (AI)-driven immune system mapping, have announced a groundbreaking multi-year partnership...
Read More